Finance

Beta
Lists
DXCM:NASDAQ
DexCom Inc
$70.14
+2.17%
(+1.49) 1D
$70.14
0.00% (0.00)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DXCM...
Open
$68.44
High
$70.38
Low
$68.28
Mkt. cap
27.07B
Avg. vol.
6.54M
Volume
6.87M
P/E ratio
30.26
52-wk high
$89.98
52-wk low
$54.11
EPS
$2.32
Beta
1.45
Shares outstanding
385.87M
No. of employees
11K
Open
$68.44
High
$70.38
Low
$68.28
Mkt. cap
27.07B
Avg. vol.
6.54M
Volume
6.87M
P/E ratio
30.26
52-wk high
$89.98
52-wk low
$54.11
EPS
$2.32
Beta
1.45
Shares outstanding
385.87M
No. of employees
11K
News stories
From sources across the web
Profile
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S., and manufacturing facilities in Mesa, Arizona, U.S.; Batu Kawan, Malaysia; and Athenry, County Galway, Ireland. Wikipedia
About DexCom Inc
CEOKevin R. Sayer
Employees11K
Founded1999
HeadquartersSan Diego, California, United States
SectorMedical device
Websitedexcom.com
Analyst ratings
Based on 22 analysts giving stock ratings to DXCM in the past 3 months
Strong buy
Buy
20
Hold
1
Sell
1
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for DXCM in the last 3 months.
Highest
Current $70.14
$112.00 (+59.68%)
Average
$83.60 (+19.19%)
Lowest
$64.00 (-8.75%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Deutsche Bank
Buy
Initiated
$86.00
+22.6%
06/25/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$88.00
+25.5%
06/15/2026
Marie Thibault
BTIG
Buy
Maintained
$80.00
+14.1%
06/15/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$95.00
+35.4%
06/10/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
$85.00
+21.2%
06/08/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
$85.00
+21.2%
06/10/2026
Jayson Bedford
Raymond James
Buy
Maintained
$91.00
+29.7%
06/08/2026
Travis Steed
Bank of America Securities
Buy
Maintained
$80.00
+14.1%
06/07/2026
Jonathan Block
Stifel Nicolaus
Buy
Reiterated
$90.00
+28.3%
06/05/2026
Joanne Wuensch
Citi
Buy
Maintained
$84.00
+19.8%
05/29/2026
William Plovanic
Canaccord Genuity
Buy
Reiterated
$82.00
+16.9%
05/19/2026
Matt Miksic
Barclays
Sell
Reiterated
$64.00
-8.8%
05/18/2026
David Roman
Goldman Sachs
Buy
Maintained
$80.00
+14.1%
05/15/2026
Unknown Analyst
Stifel Nicolaus
Buy
Maintained
$85.00
+21.2%
05/15/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
$85.00
+21.2%
05/15/2026
Richard Newitter
Truist Financial
Buy
Reiterated
-
-
05/15/2026
Lee Hambright
Bernstein
Buy
Maintained
$77.00
+9.8%
05/15/2026
Steven Lichtman
William Blair
Buy
Maintained
-
-
05/15/2026
Unknown Analyst
Jefferies
Buy
Maintained
$112.00
+59.7%
05/14/2026
Bruce Jackson
Benchmark Co.
Buy
Initiated
$77.00
+9.8%
05/11/2026
Unknown Analyst
Argus Research
Buy
Maintained
$86.00
+22.6%
05/05/2026
Robbie Marcus
J.P. Morgan
Hold
Maintained
$65.00
-7.3%
05/04/2026
Jeff Johnson
Robert W. Baird
Buy
Maintained
$80.00
+14.1%
05/01/2026
Brandon Vazquez
William Blair
Buy
Maintained
$59.00
-15.9%
05/01/2026
Suraj Kalia
Oppenheimer
Hold
Reiterated
-
-
02/13/2026
Patrick Wood
Morgan Stanley
Buy
Maintained
$75.00
+6.9%
02/13/2026
Danielle Antalffy
UBS
Buy
Reiterated
$95.00
+35.4%
02/13/2026
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$0.56 / $0.47
+18.99%beat
Revenue / Est. (USD)
1.19B / 1.17B
+1.46%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.16B
1.21B
1.26B
1.19B
Cost of goods sold
468.30M
477.90M
466.90M
441.60M
Cost of revenue
468.30M
477.90M
466.90M
441.60M
Research and development expenses
148.20M
157.50M
148.20M
145.30M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
328.00M
331.40M
321.50M
349.70M
Operating expense
476.20M
488.90M
469.70M
495.00M
Total operating expenses
944.50M
966.80M
936.60M
936.60M
Operating income
212.60M
242.50M
323.00M
255.30M
Other non operating income
5.20M
81.80M
-1.60M
-2.20M
EBT including unusual items
241.10M
352.30M
340.70M
269.50M
EBT excluding unusual items
241.10M
352.30M
340.70M
269.50M
Income tax expense
61.30M
68.50M
73.40M
70.00M
Effective tax rate
25.43%
19.44%
21.54%
25.97%
Other operating expenses
-
-
-
-
Net income
179.80M
283.80M
267.30M
199.50M
Net profit margin
15.54%
23.47%
21.22%
16.74%
Earnings per share
0.48
0.61
0.68
0.56
Interest and investment income
28.00M
32.70M
23.50M
19.50M
Interest expense
-4.70M
-4.70M
-4.20M
-3.10M
Net interest expenses
23.30M
28.00M
19.30M
16.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
275.60M
306.10M
388.20M
322.40M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of DXCM
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer